DEBIO 1143, an IAP inhibitor, reverses carboplatin resistance in ovarian cancer cells and triggers apoptotic or necroptotic cell death

[1]  S. Fulda,et al.  Identification of a synergistic combination of Smac mimetic and Bortezomib to trigger cell death in B-cell non-Hodgkin lymphoma cells. , 2017, Cancer letters.

[2]  Amy McKee,et al.  Regulatory considerations on endpoints in ovarian cancer drug development , 2017, Cancer.

[3]  K. Vuori,et al.  Inducing death in tumor cells: roles of the inhibitor of apoptosis proteins , 2017, F1000Research.

[4]  S. Fulda,et al.  Therapeutic targeting of necroptosis by Smac mimetic bypasses apoptosis resistance in acute myeloid leukemia cells , 2017, Oncogene.

[5]  T. Alain,et al.  Smac mimetics synergize with immune checkpoint inhibitors to promote tumour immunity against glioblastoma , 2017, Nature Communications.

[6]  Y. Asmann,et al.  IAP antagonists induce anti-tumor immunity in multiple myeloma , 2016, Nature Medicine.

[7]  S. Fulda,et al.  Smac mimetic triggers necroptosis in pancreatic carcinoma cells when caspase activation is blocked. , 2016, Cancer letters.

[8]  Jian Yu,et al.  Necroptosis: an alternative cell death program defending against cancer. , 2016, Biochimica et biophysica acta.

[9]  Rongying Ou,et al.  Sequential combination therapy of ovarian cancer with cisplatin and γ-secretase inhibitor MK-0752. , 2016, Gynecologic oncology.

[10]  E. Kohn,et al.  Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum‐resistant or ‐refractory epithelial ovarian cancer , 2016, Cancer.

[11]  K. Miura,et al.  The IAP Protein Family, SMAC Mimetics and Cancer Treatment. , 2016, Critical reviews in oncogenesis.

[12]  I. Ray-Coquard,et al.  Abstract C2: Clinical safety, pharmacokinetics and early evidence of activity of the oral IAPs inhibitor Debio 1143 in combination with carboplatin and paclitaxel: a phase Ib study , 2015 .

[13]  S. Fulda.  Promises and Challenges of Smac Mimetics as Cancer Therapeutics , 2015, Clinical Cancer Research.

[14]  S. Fulda,et al.  Identification of a novel synergistic induction of cell death by Smac mimetic and HDAC inhibitors in acute myeloid leukemia cells. , 2015, Cancer letters.

[15]  R. Larson,et al.  Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia--results of a phase I dose-escalation study. , 2015, Clinical lymphoma, myeloma & leukemia.

[16]  David C. Smith,et al.  Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study , 2015, Cancer Chemotherapy and Pharmacology.

[17]  G. Jayson,et al.  PARP inhibitors in BRCA mutation-associated ovarian cancer. , 2015, The Lancet Oncology.

[18]  Jia Hua Cheng,et al.  Noscapine Increases the Sensitivity of Drug-Resistant Ovarian Cancer Cell Line SKOV3/DDP to Cisplatin by Regulating Cell Cycle and Activating Apoptotic Pathways , 2014, Cell Biochemistry and Biophysics.

[19]  Henry C Kitchener,et al.  Ovarian cancer , 2014, The Lancet.

[20]  N. Cosford,et al.  Triggering necroptosis in cisplatin and IAP antagonist-resistant ovarian carcinoma , 2014, Cell Death and Disease.

[21]  S. Fulda,et al.  Smac mimetic primes apoptosis-resistant acute myeloid leukaemia cells for cytarabine-induced cell death by triggering necroptosis. , 2014, Cancer letters.

[22]  Liu Liu,et al.  Potent and Selective Small-Molecule Inhibitors of cIAP1/2 Proteins Reveal That the Binding of Smac Mimetics to XIAP BIR3 Is Not Required for Their Effective Induction of Cell Death in Tumor Cells , 2014, ACS chemical biology.

[23]  R. Korneluk,et al.  Smac mimetics and innate immune stimuli synergize to promote tumor death , 2014, Nature Biotechnology.

[24]  F. Vasile,et al.  Antitumor activity of a novel homodimeric SMAC mimetic in ovarian carcinoma. , 2014, Molecular pharmaceutics.

[25]  M. Colombo,et al.  Smac mimetics induce inflammation and necrotic tumour cell death by modulating macrophage activity , 2013, Cell Death and Disease.

[26]  A. Rafii,et al.  Microenvironment mesenchymal cells protect ovarian cancer cell lines from apoptosis by inhibiting XIAP inactivation , 2013, Cell Death and Disease.

[27]  Tao Zhang,et al.  Physiologically based pharmacokinetic and pharmacodynamic modeling of an antagonist (SM‐406/AT‐406) of multiple inhibitor of apoptosis proteins (IAPs) in a mouse xenograft model of human breast cancer , 2013, Biopharmaceutics & drug disposition.

[28]  Liu Liu,et al.  A potent bivalent Smac mimetic (SM-1200) achieving rapid, complete, and durable tumor regression in mice. , 2013, Journal of medicinal chemistry.

[29]  R. Korneluk,et al.  Modulation of immune signalling by inhibitors of apoptosis. , 2012, Trends in immunology.

[30]  D. Vučić,et al.  The inhibitor of apoptosis (IAP) proteins are critical regulators of signaling pathways and targets for anti-cancer therapy. , 2012, Experimental oncology.

[31]  Shaomeng Wang,et al.  AT-406, an orally active antagonist of multiple inhibitor of apoptosis proteins, inhibits progression of human ovarian cancer , 2012, Cancer biology & therapy.

[32]  M. Biffoni,et al.  A Small Molecule SMAC Mimic LBW242 Potentiates TRAIL- and Anticancer Drug-Mediated Cell Death of Ovarian Cancer Cells , 2012, PloS one.

[33]  S. Fulda,et al.  Requirement of nuclear factor κB for Smac mimetic-mediated sensitization of pancreatic carcinoma cells for gemcitabine-induced apoptosis. , 2011, Neoplasia.

[34]  Tao Zhang,et al.  A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. , 2011, Journal of medicinal chemistry.

[35]  D. Vaux,et al.  Smac Mimetics Activate the E3 Ligase Activity of cIAP1 Protein by Promoting RING Domain Dimerization* , 2011, The Journal of Biological Chemistry.

[36]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[37]  S. Fulda,et al.  TRAIL-Induced Apoptosis Is Preferentially Mediated via TRAIL Receptor 1 in Pancreatic Carcinoma Cells and Profoundly Enhanced by XIAP Inhibitors , 2010, Clinical Cancer Research.

[38]  N. Hacohen,et al.  IAP inhibitors enhance co-stimulation to promote tumor immunity , 2010, The Journal of experimental medicine.

[39]  Pascal Meier,et al.  IAPs: from caspase inhibitors to modulators of NF-κB, inflammation and cancer , 2010, Nature Reviews Cancer.

[40]  Jia-jia Ma,et al.  XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma. , 2009, European journal of obstetrics, gynecology, and reproductive biology.

[41]  Kathleen R. Cho,et al.  Ovarian cancer. , 2009, Annual review of pathology.

[42]  Shaomeng Wang,et al.  SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP. , 2008, Cancer research.

[43]  I. Tannock,et al.  Drug resistance and the solid tumor microenvironment. , 2007, Journal of the National Cancer Institute.

[44]  J. Nesland,et al.  Nuclear expression of survivin is associated with improved survival in metastatic ovarian carcinoma , 2007, Cancer.

[45]  John Calvin Reed,et al.  Distinct BIR Domains of cIAP1 Mediate Binding to and Ubiquitination of Tumor Necrosis Factor Receptor-associated Factor 2 and Second Mitochondrial Activator of Caspases* , 2006, Journal of Biological Chemistry.

[46]  D. Ma,et al.  Regulation of HtrA2/Omi by X-linked inhibitor of apoptosis protein in chemoresistance in human ovarian cancer cells. , 2005, Gynecologic oncology.

[47]  R. Korneluk,et al.  XIAP: Apoptotic brake and promising therapeutic target , 2001, Apoptosis.

[48]  L. Tian,et al.  Cisplatin resistance in an ovarian carcinoma is associated with a defect in programmed cell death control through XIAP regulation. , 2003, Oncology research.

[49]  Yasuo Watanabe,et al.  Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors. , 2002, International journal of oncology.

[50]  Y. Sheng,et al.  Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells. , 2000, Cancer research.

[51]  J C Reed,et al.  IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. , 1998, Cancer research.

[52]  S. Orsulic,et al.  Ovarian Cancer , 1993, British Journal of Cancer.